Interleukin inhibitors market was valued at $28.8 billion in 2025 and is projected to reach $79.0 billion by 2035, growing at a CAGR of 10.6% during the forecast period (2026-2035). The rising prevalence of chronic inflammatory skin disorders is contributing to sustained growth in the global interleukin inhibitors market. Atopic dermatitis (AD), the most common form of eczema, affects approximately 16.5 million adults in the US, with nearly 6.6 million classified as moderate to severe cases in 2025. In addition, around 9.6 million children under the age of 18 are affected, with one-third experiencing moderate to severe disease. The increasing disease burden has accelerated the adoption of targeted biologic therapies, particularly IL-4, IL-13, IL-17, and IL-23 inhibitors. Market player such as Sanofi maintains a leading position in this space through Dupixent (dupilumab), an IL-4/IL-13 inhibitor widely regarded as a standard biologic therapy for AD. The therapy generated more than $13 billion in global sales in 2024, with atopic dermatitis remaining its primary indication, reflecting strong clinical uptake and sustained demand.
Browse the full report description of “Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/interleukin-inhibitors-market
Furthermore other diseases such as psoriasis further adds to the global burden, impacting nearly 2% of the global population, equivalent to approximately 125–140 million individuals globally. The therapeutic landscape for psoriasis has evolved significantly with the emergence of IL-17 and IL-23 inhibitors, which have demonstrated improved efficacy, durable response rates, and favorable safety profiles compared to earlier systemic therapies. As of 2026, more than 8 million individuals in the US are living with psoriasis, while global estimates indicate that 2–3% of the population is affected. Approximately 30% of psoriasis patients develop psoriatic arthritis, further expanding the addressable patient population for IL-targeted treatments. As of 2026, 11 biologic agents are approved by the FDA for moderate-to-severe psoriasis, underscoring the maturity and competitiveness of the segment. Continued advancements in cytokine-specific targeting, lifecycle management strategies, and expanded indications are shaping market dynamics. Major pharmaceutical companies are increasing research investments and strengthening development pipelines to enhance treatment durability, optimize dosing regimens, and address unmet needs across dermatology and immunology. Collectively, these factors are expected to sustain long-term growth opportunities within the global IL inhibitors market.
Key Players and Recent Developments in the Global Interleukin Inhibitors Market
The major companies present in the global interleukin inhibitors market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Sanofi S.A. among others. These major companies are actively investing in research and development to expand their biologics portfolios, focusing on next-generation interleukin inhibitors targeting IL-4, IL-5, IL-13, IL-17, and IL-23 pathways. They are also pursuing strategic collaborations, regulatory approvals, and geographic expansion to strengthen their market presence and address rising demand for advanced immunology therapies.
Market Coverage
Key questions addressed by the report.
Global Interleukin Inhibitors Market Report Segment
By Type
By Application
Global Interleukin Inhibitors Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/interleukin-inhibitors-market